Search

Displaying results 1581 - 1590 of 4234 in total
  1. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary

  2. Drug

    Prilocaine

    go.drugbank.com/drugs/DB00750
    ApprovedInvestigational

    A local anesthetic that is similar pharmacologically to lidocaine. Currently, it is used most often for infiltration anesthesia in dentistry. (From AMA Drug Evaluations Annual, 1992, p165)

  3. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    Teplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS. … [A241480] On November 2022, teplizumab was approved by the FDA as the first drug that can delay the onset of type 1 diabetes.

  4. Drug

    Thenalidine

    go.drugbank.com/drugs/DB04826
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.

  5. Drug

    Cianidanol

    go.drugbank.com/drugs/DB14086
    ApprovedInvestigationalWithdrawn

    An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.

  6. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    [L51078]The US FDA subsequently approved insulin icodec in March 2026 for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [L56102] … [L51078] In July 2024, the US FDA rejected the approval of insulin icodec, citing concerns regarding hypoglycemia and the indication being sought for type 1 diabetes mellitus.

  7. Drug

    Phenolphthalein

    go.drugbank.com/drugs/DB04824
    ApprovedWithdrawn

    Phenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.

  8. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    Therefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this group of patients. … [A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress.

  9. Drug

    Reserpine

    go.drugbank.com/drugs/DB00206
    ApprovedWithdrawn

    It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.

  10. Drug

    Rifaximin

    go.drugbank.com/drugs/DB01220
    ApprovedInvestigational

    It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel … Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered